Ferrous iron content of intravenous iron formulations

BioMetals

Volumn 29, Issue 3, 2016, Pages 411-415

  Gupta, Ajay ^a,b   Pratt, Raymond D ^b   Crumbliss, Alvin L ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Rockwell Medical Technologies Inc   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

Chronic hemodialysis; Ferric iron; Ferrous iron; Intravenous iron; Iron supplementation

Indexed keywords

ASCORBIC ACID; FERRIC CARBOXYMALTOSE; FERRIC ION; FERROUS GLUCONATE; FERROUS ION; FERROZINE; FERUMOXYTOL; FREE RADICAL; IRON DEXTRAN; IRON SACCHARATE; REACTIVE OXYGEN METABOLITE; SEQUESTERING AGENT; SIDEROPHORE; FERRIC GLUCONATE; MAGNETITE; MALTOSE; SACCHARIC ACID;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; INFECTION RISK; ULTRAVIOLET SPECTROSCOPY; ANALOGS AND DERIVATIVES; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; FERRIC COMPOUNDS; FERROSOFERRIC OXIDE; FERROUS COMPOUNDS; GLUCARIC ACID; IRON-DEXTRAN COMPLEX; MALTOSE;

EID: 84960117856     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-016-9923-7     Document Type: Article

References (14)

1. Barton Pai A, Pai MP, Depczynski J, McQuade CR, Mercier RC (2006) Non-transferrin-bound iron is associated with enhanced Staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose. Am J Nephrol 26:304–309. doi:10.1159/000094343
2. Beshara S, Lundqvist H, Sundin J, Lubberink M, Tolmachev V, Valind S, Antoni G, Långström B, Danielson BG (1999) Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol 104:296–302
3. Brookhart MA, Freburger JK, Ellis AR, Winkelmayer WC, Wang L, Kshirsagar AV (2016) Comparative short-term safety of sodium ferric gluconate versus iron sucrose in hemodialysis patients. Am J Kidney Dis 67:119–127. doi:10.1053/j.ajkd.2015.07.026
4. Crichton RR, Boelaert JR (2001) Inorganic biochemistry of iron metabolism: from molecular mechanisms to clinical consequences, 2nd edn. Wiley, New York
5. European Medicines Agency (2013) Reflection paper on data requirements for intravenous iron-based nono-colloidal products developed with reference to an innovator medicinal product. vol EMA/CHMP/SWP/620008/2012. European Medicines Agency, London
6. Farkas E, Enyedy EA, Zekany L, Deak G (2001) Interaction between iron(II) and hydroxamic acids: oxidation of iron(II) to iron(III) by desferrioxamine B under anaerobic conditions. J Inorg Biochem 83:107–114
7. Fell LH, Zawada AM, Rogacev KS, Seiler S, Fliser D, Heine GH (2014) Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant 29:809–822. doi:10.1093/ndt/gft524
8. Geisser P, Burckhardt S (2011) The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 3:12–33. doi:10.3390/pharmaceutics3010012
9. Helm L, Merbach AE (2005) Inorganic and bioinorganic solvent exchange mechanisms. Chem Rev 105:1923–1959. doi:10.1021/cr030726o
10. Neiser S, Rentsch D, Dippon U, Kappler A, Weidler PG, Göttlicher J, Steininger R, Wilhelm M, Braitsch M, Funk F, Philipp E, Burckhardt S (2015) Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. Biometals 28:615–635. doi:10.1007/s10534-015-9845-9
11. Roeser HP, Lee GR, Nacht S, Cartwright GE (1970) The role of ceruloplasmin in iron metabolism. J Clin Investig 49:2408–2417. doi:10.1172/JCI106460
12. Sirken G, Raja R, Rizkala AR (2006) Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients. Clin Nephrol 66:348–356
13. Stefansson BV, Haraldsson B, Nilsson U (2011) Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran. Nephron Clin Pract 118:c249–c256. doi:10.1159/000321645
14. Wang S, Geraci G, Kuhlmann MK, Levin NW, Handelman GJ (2008) Chemical reactions of vitamin C with intravenous-iron formulations. Nephrol Dial Transplant 23:120–125. doi:10.1093/ndt/gfm557